Physiological and Pharmaceutical Considerations for Rectal Drug Formulations
- PMID:31680970
- PMCID: PMC6805701
- DOI: 10.3389/fphar.2019.01196
Physiological and Pharmaceutical Considerations for Rectal Drug Formulations
Abstract
Although the oral route is the most convenient route for drug administration, there are a number of circumstances where this is not possible from either a clinical or pharmaceutical perspective. In these cases, the rectal route may represent a practical alternative and can be used to administer drugs for both local and systemic actions. The environment in the rectum is considered relatively constant and stable and has low enzymatic activity in comparison to other sections of the gastrointestinal tract. In addition, drugs can partially bypass the liver following systemic absorption, which reduces the hepatic first-pass effect. Therefore, rectal drug delivery can provide significant local and systemic levels for various drugs, despite the relatively small surface area of the rectal mucosa. Further development and optimization of rectal drug formulations have led to improvements in drug bioavailability, formulation retention, and drug release kinetics. However, despite the pharmaceutical advances in rectal drug delivery, very few of them have translated to the clinical phase. This review will address the physiological and pharmaceutical considerations influencing rectal drug delivery as well as the conventional and novel drug delivery approaches. The translational challenges and development aspects of novel formulations will also be discussed.
Keywords: nanoparticles; dosage form; drug delivery; drug formulation; physiological considerations; rectal; rectum; translation.
Copyright © 2019 Hua.
Similar articles
- Pharmacokinetics of rectal drug administration, Part I. General considerations and clinical applications of centrally acting drugs.van Hoogdalem E, de Boer AG, Breimer DD.van Hoogdalem E, et al.Clin Pharmacokinet. 1991 Jul;21(1):11-26. doi: 10.2165/00003088-199121010-00002.Clin Pharmacokinet. 1991.PMID:1717195Review.
- Advancements in Rectal Drug Delivery Systems: Clinical Trials, and Patents Perspective.Rathi R, Sanshita, Kumar A, Vishvakarma V, Huanbutta K, Singh I, Sangnim T.Rathi R, et al.Pharmaceutics. 2022 Oct 17;14(10):2210. doi: 10.3390/pharmaceutics14102210.Pharmaceutics. 2022.PMID:36297645Free PMC article.Review.
- Rectal drug administration: clinical pharmacokinetic considerations.de Boer AG, Moolenaar F, de Leede LG, Breimer DD.de Boer AG, et al.Clin Pharmacokinet. 1982 Jul-Aug;7(4):285-311. doi: 10.2165/00003088-198207040-00002.Clin Pharmacokinet. 1982.PMID:6126289Review.
- Advances in Oral Drug Delivery for Regional Targeting in the Gastrointestinal Tract - Influence of Physiological, Pathophysiological and Pharmaceutical Factors.Hua S.Hua S.Front Pharmacol. 2020 Apr 28;11:524. doi: 10.3389/fphar.2020.00524. eCollection 2020.Front Pharmacol. 2020.PMID:32425781Free PMC article.Review.
- Advances in Nanoparticulate Drug Delivery Approaches for Sublingual and Buccal Administration.Hua S.Hua S.Front Pharmacol. 2019 Nov 5;10:1328. doi: 10.3389/fphar.2019.01328. eCollection 2019.Front Pharmacol. 2019.PMID:31827435Free PMC article.Review.
Cited by
- Efficacy of mucosal vaccination using a protozoan parasite as a vehicle for antigen delivery: IgG and neutralizing response after rectal administration of LeCoVax-2, a candidate vaccine against COVID-19.Epis S, Varotto-Boccazzi I, Manenti A, Rubolini D, Gabrieli P, Cattaneo GM, Gourlay L, Dapporto F, Monti M, Razzano I, Leonardi M, Iannacone M, Recordati C, Bertola L, Fiorina P, Marvasi L, Montomoli E, Zuccotti G, Bandi C.Epis S, et al.Pharmacol Res. 2022 Dec;186:106546. doi: 10.1016/j.phrs.2022.106546. Epub 2022 Nov 4.Pharmacol Res. 2022.PMID:36336215Free PMC article.
- Characterisation of rectal amoxicillin (RAMOX) for the treatment of pneumonia in children.Hanning SM, Matiz S, Krasser K, Orlu M, Dodoo C, Gaisford S, Tuleu C.Hanning SM, et al.Drug Deliv Transl Res. 2021 Jun;11(3):944-955. doi: 10.1007/s13346-020-00804-6.Drug Deliv Transl Res. 2021.PMID:32588280Free PMC article.
- 3D printed infliximab suppositories for rectal biologic delivery.Awad A, Goyanes A, Orlu M, Gaisford S, Basit AW.Awad A, et al.Int J Pharm X. 2023 Mar 8;5:100176. doi: 10.1016/j.ijpx.2023.100176. eCollection 2023 Dec.Int J Pharm X. 2023.PMID:37396625Free PMC article.
- Defining the next generation of severe malaria treatment: a target product profile.Achan J, Barry A, Leroy D, Kamara G, Duparc S, Kaszubska W, Gandhi P, Buffet B, Tshilab P, Ogutu B, Taylor T, Krishna S, Richardson N, Ramachandruni H, Rietveld H.Achan J, et al.Malar J. 2024 Jun 5;23(1):174. doi: 10.1186/s12936-024-04986-z.Malar J. 2024.PMID:38835069Free PMC article.Review.
- Delivery of Dihydroergotamine Mesylate to the Upper Nasal Space for the Acute Treatment of Migraine: Technology in Action.Cooper W, Ray S, Aurora SK, Shrewsbury SB, Fuller C, Davies G, Hoekman J.Cooper W, et al.J Aerosol Med Pulm Drug Deliv. 2022 Dec;35(6):321-332. doi: 10.1089/jamp.2022.0005. Epub 2022 Sep 14.J Aerosol Med Pulm Drug Deliv. 2022.PMID:36108289Free PMC article.Review.
References
- Abd el-Gawad A. H., Din E. Z., Abd el-Alim H. A. (1988). Effect of surfactant incorporation techniques on sulphamethoxazole suppository formulations. Pharmazie 43 (9), 624–627. - PubMed
Publication types
Related information
LinkOut - more resources
Full Text Sources
Other Literature Sources